Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

vatalanib

An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CGP79787D
PTK787/ZK 222584
Code name:CGP-79787
PTK787
ZK 222584
Chemical structure:1-[4-Chloroanilino]-4-[4-pyridylmethyl]phthalazine Succinate
1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1)
NSC code:719335
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search